Patent · US Active

Analogs of glycyl-prolyl-glutamate

US7863304B2 · kind B2 · utility

7Cited by

3References

14Claims

0Family size

Assignee

Neuren Pharmaceuticals Limited · NL

Inventors

Margaret Anne Brimble · Hamilton, NZ
Paul William Richard Harris · Richmond, US
Frank Sieg · Auckland, NZ

Key dates

Filing date	Nov 20, 2007
Grant date	Jan 4, 2011
Priority date	—
Expiry date	Oct 12, 2028

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07D487/10
WIPO fieldOrganic fine chemistry
WIPO sectorChemistry

Abstract

Embodiments of this invention include novel analogs of Glycyl-Prolyl-Glutamate (GPE) and compositions containing such analogs of GPE. Of these, certain analogs have modified proline residues. Other embodiments of this invention include uses of analogs of GPE to protect neural cells from degeneration and/or death in response to injury or disease. Disorders treatable with compounds and compositions of this invention include hypoxia/ischemia, toxic injury, and chronic neurodegenerative disorders including Parkinson's disease.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.